ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Analytical Technical Leader at Vaxcyte - ApplyBlast

Analytical Technical Leader

Vaxcyte

3 months ago

3.9 on Glassdoor

San Carlos, California, United States

Hybrid

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Analytical Technical Leader (ATL) is a strategic, matrixed role within Vaxcyte’s global vaccine organization, responsible for coordinating analytical activities across development, quality control, regulatory, and manufacturing functions and external partners. The ATL drives alignment, compliance, and innovation without direct line management, influencing cross‑functional teams to ensure analytical readiness and support audit and regulatory submissions.

Responsibilities

Coordinate cross‑functional analytical strategies across development, QC, regulatory, and manufacturing
Oversee analytical readiness, scalability, and regulatory compliance of methods and documentation
Provide technical leadership and influence decision‑making for global analytical teams

Skills

Qualifications

Bachelor degree in Analytical Chemistry, Pharmaceutical Sciences, or related field

About Vaxcyte

vaxcyte.com

Headquarters

San Carlos, California, United States

Company Size

51-200 employees

Founded

2013

View Profile

Vaxcyte is a clinical-stage vaccine innovation company dedicated to eliminating bacterial infections — including invasive pneumococcal disease, Group A Strep, and Shigella — using advanced chemistry and a proprietary cell-free protein synthesis platform. Its lead programs, VAX-31 (a 31-valent PCV) and VAX-24 (a 24-valent PCV), are being evaluated in Phase 3 trials for the prevention of invasive pneumococcal disease, with additional early-stage candidates targeting Group A Strep and Shigella. Vaxcyte is also investing up to $1 billion in U.S. biomanufacturing expansion to support scalable vaccine production.